Last update 14 Dec 2024
Trastuzumab biosimilar (Hisun Pharma)
Last update 14 Dec 2024
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms Trastuzumab biosimilar, HS-022, 安瑞泽 |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (28 Feb 2023), |
Regulation- |
Login to view timeline
Gene Sequence
Sequence Code 18481L
The sequence is quoted from: *****
Sequence Code 44772H
The sequence is quoted from: *****
Related
4
Clinical Trials associated with Trastuzumab biosimilar (Hisun Pharma)Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive breast cancer
比较安瑞泽联合长春瑞滨与赫赛汀联合长春瑞滨治疗HER2阳性转移性乳腺癌的有效性、安全性和免疫原性的III期临床试验
[Translation] Phase III clinical trial comparing the efficacy, safety and immunogenicity of Anruiza combined with vinorelbine and Herceptin combined with vinorelbine in the treatment of HER2-positive metastatic breast cancer
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer
100 Clinical Results associated with Trastuzumab biosimilar (Hisun Pharma)
Login to view more data
100 Translational Medicine associated with Trastuzumab biosimilar (Hisun Pharma)
Login to view more data
100 Patents (Medical) associated with Trastuzumab biosimilar (Hisun Pharma)
Login to view more data
100 Deals associated with Trastuzumab biosimilar (Hisun Pharma)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| HER2 Positive Breast Cancer | CN | 28 Feb 2023 | |
| Stomach Cancer | CN | 28 Feb 2023 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 3 | CN | 16 May 2018 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free